Cardium Therapeutics, Inc. (CXM) Engages MissionIR for Strategic Investor Relations Services

MissionIR will be assisting Cardium Therapeutics in the implementation of a strategic digital and social media investor relations campaign. Through a network of investor-oriented sites and a full suite of investor awareness services, MissionIR develops and executes investor awareness plans for companies in the small-cap markets.
“Cardium has clearly demonstrated their dedication to building on core products and product candidates to continually create new opportunities for greater success,” stated Sherri Snyder, Director of Marketing at MissionIR. “Leveraging the advantages of its capital-efficient, asset-based business strategy, Cardium provides a diversified and more balanced portfolio of risk/return opportunities with the chief objective of providing long-term shareholder value.”
A health sciences and regenerative medicine company, Cardium is focused on the acquisition and strategic development of new and innovative bio-medical product opportunities and businesses with the potential to address significant unmet medical needs that have definable pathways to commercialization, partnering, and other economic monetizations. Cardium’s current medical opportunities portfolio, which is focused on health sciences and regenerative medicine, includes the Tissue Repair Company, Cardium Biologics, and the Company’s in-house MedPodium Health Sciences healthy lifestyle product platform.

For more information, visit

Please see disclaimer on the MissionIR website: